So far, these are Contagion's 5 most-read stories of 2023.
Unfortunately (but inevitably), infectious disease followed us into 2023.
Despite failing to meet primary trial endpoints, molnupiravir reduced the length of COVID-19 infection by 4.2 days in vaccinated patients.
Developed by Sanofi and AstraZeneca, the single-dose long-acting antibody was designed to help protect all infants from birth through their first respiratory syncytial virus (RSV) season.
In just a month, the XBB.1.5 variant went from causing 1% to over 40% of new COVID-19 infections.
Health programs and efforts to inform the public about the importance of sharing liver education can play a major role in prevention as well as patient care.
The 24-valent investigational pneumococcal conjugate vaccine, VAX-24, met its primary endpoints in a phase 1/2 trial.